定制代谢检查能否减少泌尿系结石复发?一项叙述性综述
本叙述性综述检索了1980年1月至2026年3月的文献,评估个体化代谢检查及针对性饮食和药物治疗能否减少结石复发。结果显示纠正特定尿液异常的干预措施均能降低复发风险,高危和术后患者获益最明确,且预防复发具有成本效益。
要点
- 纠正特定尿液异常的干预可降低结石复发,增加液体摄入约减半复发风险。
- 靶向药物治疗进一步降低复发,但NOSTONE试验未发现噻嗪类显著获益。
- 定制预防在高危、复发及术后结石患者中证据最强。
核心结论
- 定制预防最适合复发、高危和术后结石患者,识别并纠正异常、确保依从并复查确认反应可最大程度减少复发。
研究设计与样本
- 叙述性综述检索PubMed/MEDLINE、Cochrane Library和Europe PMC(1980年1月至2026年3月),纳入随机试验、对照队列和系统综述,并补充EAU、AUA、NICE和ACP指南及手工检索参考文献。
主要发现
- 增加液体摄入约减半结石复发(RR 0.45-0.55)。
- 正常钙、低钠、低动物蛋白饮食在高钙尿性草酸钙结石形成者中达到类似减少(RR 0.49)。
- 靶向药物治疗进一步降低复发:枸橼酸钾RR约0.25,噻嗪类0.52,别嘌醇0.59;但NOSTONE试验未发现噻嗪类显著获益。
- 冲击波碎石和经皮肾镜取石术后,药物治疗减少结石形成和残留碎片再生。
- 24小时尿液导向治疗优于经验性治疗的证据仅限于高危患者,选择性治疗显著减少结石相关事件。
关键数值与推荐
- 增加液体摄入RR 0.45-0.55;正常钙、低钠、低动物蛋白饮食RR 0.49;枸橼酸钾RR约0.25;噻嗪类RR 0.52;别嘌醇RR 0.59。
临床怎么用
- 对复发、高危和术后结石患者应进行定制代谢评估,识别并纠正特定尿液异常。
- 确保患者依从饮食和药物治疗,并通过重复检测确认反应。
- 结石病损害疾病特异性生活质量且花费高,预防复发可节省费用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine whether individualised ('bespoke') metabolic investigation and targeted dietary and medical therapy reduces urinary stone recurrence, and whether the approach also improves health-related quality of life (HRQOL) and lowers financial and environmental cost. METHODS: In this narrative review we searched PubMed/Medical Literature Analysis and Retrieval System Online (MEDLINE), the Cochrane Library and Europe PubMed Central (PMC) (January 1980 to March 2026) for randomised trials, controlled cohorts and systematic reviews on metabolic assessment and stone recurrence prevention in adults, supplemented by European Association of Urology (EAU), American Urological Association (AUA), National Institute for Health and Care Excellence (NICE) and American College of Physicians (ACP) guidance and by hand-searching of reference lists. RESULTS: Interventions that correct a defined urinary abnormality each reduce stone recurrence. Increased fluid intake approximately halves it (relative risk [RR] 0.45-0.55); a normal calcium, reduced sodium, reduced animal protein diet achieves a similar reduction in hypercalciuric calcium-oxalate formers (RR 0.49); and targeted pharmacotherapy lowers it further (potassium citrate RR approximately 0.25, thiazides 0.52, allopurinol 0.59), although the rigorous NOSTONE trial (ClinicalTrials.gov identifier: NCT03057431) found no significant thiazide benefit. After shockwave lithotripsy and percutaneous nephrolithotomy, medical therapy reduces stone formation and residual-fragment regrowth. Evidence that 24-h-urine-directed therapy outperforms empirical therapy is confined to high-risk patients, in whom selective treatment yields significantly fewer stone-related events. Stone disease impairs disease-specific quality of life and is costly, so preventing stone recurrence is cost-saving. CONCLUSIONS: The case for bespoke prevention is strongest in recurrent, high-risk and post-procedural stone formers. Identifying the abnormality, correcting it, ensuring adherence and confirming the response by repeat testing offers the best chance to reduce stone recurrence and residual-stone growth, improve HRQOL, and lower financial cost.
引用
- Wiseman OJ, Turney BW. Does bespoke metabolic investigation reduce urinary stone recurrence? A narrative review. BJU Int. 2026. PMID: 42901875. doi:10.1111/bju.70500
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。